148580-25-0 Usage
Description
HMR 1826 is a heterodimeric lucuronide prodrug of doxorubicin (D558000), an anthracycline antibiotic. It is designed to enhance the delivery and efficacy of doxorubicin, which is a widely used chemotherapy drug for the treatment of various types of cancer.
Uses
Used in Oncology:
HMR 1826 is used as a chemotherapy agent for the treatment of a wide range of cancers. It is particularly effective due to its ability to deliver doxorubicin, a potent antineoplastic agent, directly to cancer cells, thereby reducing systemic side effects and increasing the therapeutic index.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, HMR 1826 is used as a drug candidate for the development of novel cancer therapies. Its unique structure allows for targeted delivery of doxorubicin, making it a promising option for patients with cancer who may not respond well to traditional chemotherapy treatments or who have developed resistance to other drugs.
Used in Drug Delivery Systems:
HMR 1826 is also used in the development of advanced drug delivery systems, such as nanoparticles and liposomes, to improve the bioavailability and targeting of doxorubicin. These systems aim to enhance the therapeutic outcomes of doxorubicin by reducing its toxicity and increasing its specificity towards cancer cells.
Check Digit Verification of cas no
The CAS Registry Mumber 148580-25-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,8,5,8 and 0 respectively; the second part has 2 digits, 2 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 148580-25:
(8*1)+(7*4)+(6*8)+(5*5)+(4*8)+(3*0)+(2*2)+(1*5)=150
150 % 10 = 0
So 148580-25-0 is a valid CAS Registry Number.
148580-25-0Relevant articles and documents
Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy
Florent, Jean-Claude,Dong, Xia,Gaudel, Gilbert,Mitaku, Sofia,Monneret, Claude,Gesson, Jean-Pierre,Jacquesy, Jean-Claude,Mondon, Martine,Renoux, Brigitte,Andrianomenjanahary, Solo,Michel, Sylvie,Koch, Michel,Tillequin, Fran?ois,Gerken, Manfred,Czech, Joerg,Straub, Rainer,Bosslet, Klaus
, p. 3572 - 3581 (2007/10/03)
A series of new prodrugs of daunorubicin and doxorubicin which are candidates for antibody-directed enzyme prodrug therapy (ADEPT) is reported. These compounds (25a,b,c and 32a,b,c) have been designed to generate cytotoxic drugs after activation with β-gl
